Aaron Kantoff is a principal at Apple Tree Partners, a New York-based venture capital firm that is Syntimmue’s lead investor. He brings deep early and late-stage biotech experience to Syntimmune, as well as a background in financial analysis and restructuring. Prior to joining Apple Tree in 2011, Aaron was a partner at Recess Global LLC, an investment company he founded to focus on startup funding. Prior to Recess Global, Aaron was a member of the investment banking team at Rothschild Inc., in the Restructuring Group.
In addition to his role with Apple Tree, Aaron has also served as Executive Director of Business Development & Corporate Strategy of Braeburn Pharmaceuticals, a commercial-stage company delivering individualized medicine for the treatment of central nervous system disorders. He currently serves as a director of Elstar Therapeutics and Limelight Bio, and is a board observer at Corvidia Therapeutics.